A higher sialylation of the N-glycans in the IgA anti-HER2 did not interfere in the anti-tumour response and lead to the decrease in tumour growth in FcαRI transgenic mice, while increasing the antibody half-life [140]. The gene discussed is CD79A; the disease is neoplasm.